Zevra Therapeutics

Zevra Therapeutics

Quarterly Financials

Values in thousands2026-09-302026-06-302026-03-312025-12-31
Revenue
$37,756
$39,663
$36,220
$34,125
Gross Profit
35,646
38,138
33,955
32,605
EBITDA
11,896
13,158
43,461
14,976
EBIT
11,580
12,794
43,093
14,614
Net Income
19,208
8,752
37,890
12,165
Net Change In Cash
37,756
39,663
36,220
34,125
Free Cash Flow
9,809
16,815
6,107
5,547
Cash
122,148
145,321
95,595
62,406
Basic Shares
61,732
61,336
60,230
57,262

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$106,470
$23,612
$27,461
$10,161
Gross Profit
89,988
16,195
24,516
9,939
EBITDA
98,709
-76,400
-43,542
-25,526
EBIT
94,655
-82,789
-44,548
-26,470
Net Income
83,229
-105,511
-46,049
-26,772
Net Change In Cash
106,470
23,612
27,461
10,161
Free Cash Flow
-2,433
-69,665
-33,831
-18,810
Cash
62,406
33,785
43,049
65,466
Basic Shares
57,262
46,251
35,452
34,488

Earnings Calls

QuarterEPS
2026-09-30
$0.18
2026-06-30
$0.25
2026-03-31
$0.18
2025-12-31
$0.19